|Bid||31.22 x 800|
|Ask||35.86 x 1000|
|Day's range||35.18 - 36.08|
|52-week range||28.42 - 39.47|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||6.98|
|Earnings date||05 May 2022|
|Forward dividend & yield||1.12 (3.33%)|
|Ex-dividend date||13 May 2022|
|1y target est||39.43|
JERSEY CITY, N.J., June 13, 2022--Organon announces first biosimilars business deal with a global license agreement with Henlius.
The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...
STOCKHOLM, June 02, 2022--Global women’s health company, Organon (NYSE: OGN), which employs 9,300 people globally, including 85 in its operations across the Nordics today announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report for 2021. The ESG report introduces the company’s ESG platform, known as Her Promise, and details how the company is working to help women and girls achieve the full potential of their promise through better health. The publication of